Preliminary communication

https://doi.org/10.20471/acc.2020.59.02.19

Adropin – Potential Link in Cardiovascular Protection for Obese Male Type 2 Diabetes Mellitus Patients Treated with Liraglutide

Tina Tičinović Kurir ; Department of Endocrinology and Diabetes, Split University Hospital Centre Split, Croatia; Department of Pathophysiology, University of Split School of Medicine, Split, Croatia
Tanja Miličević ; Department of Endocrinology and Diabetes, Split University Hospital Centre Split, Croatia
Anela Novak ; Department of Endocrinology and Diabetes, Split University Hospital Centre Split, Croatia
Marino Vilović ; Department of Pathophysiology, University of Split School of Medicine, Split, Croatia
Joško Božić ; Department of Pathophysiology, University of Split School of Medicine, Split, Croatia

Abstract

The aim of this study was to determine plasma adropin concentration and parameters of insulin resistance in obese male type 2 diabetes mellitus (T2DM) patients before and after 3-month liraglutide treatment. In this interventional study, we enrolled 15 obese male T2DM patients with body mass index (BMI) >35 kg/m2, uncontrolled disease and HbA1c >7.5%, having previously taken taking two oral antidiabetic drugs. We modified their therapy to metformin and liraglutide for the next three months. After three months of liraglutide treatment, we observed significant decrease in body weight (from 111.5±18.7 kg to 109.2±17.5 kg, p=0.016) and BMI (from 40.9±7.3 to 40.1±7.0 kg/m2, p=0.021). Plasma adropin concentration increased significantly (p=0.003) compared with baseline. Fasting plasma insulin level decreased from 17.79±6.53 to 13.38±3.51 mU/L (p=0.002), fasting plasma glucose level decreased from 8.66±3.07 to 7.41±2.21 mmol/L (p=0.004) and HbA1c decreased from 7.98±0.70% to 7.26±0.36% (p=0.003). Insulin resistance presented as HOMA-IR decreased significantly from 7.30±5.19 to 4.52±2.61 (p=0.002). Systolic blood pressure, lipid status, liver and kidney function improved, but not reaching statistical significance. Treating obese male T2DM patients with liraglutide resulted in a significantly higher plasma adropin concentration, significant weight loss and improved parameters of insulin resistance, i.e. decreased fasting plasma insulin, plasma glucose levels and HOMA-IR.

Keywords

Diabetes mellitus type 2; Insulin resistance; Obesity; Adropin; Liraglutide; Endothelial cell dysfunction

Hrčak ID:

243695

URI

https://hrcak.srce.hr/243695

Publication date:

1.6.2020.

Article data in other languages: croatian

Visits: 2.532 *